Published in Rheumatol Ther on December 08, 2016
Cold Atmospheric Plasma in the Treatment of Osteosarcoma. Int J Mol Sci (2017) 0.75
miR-216a inhibits osteosarcoma cell proliferation, invasion and metastasis by targeting CDK14. Cell Death Dis (2017) 0.75
MicroRNA-93 promotes cell proliferation by directly targeting P21 in osteosarcoma cells. Exp Ther Med (2017) 0.75
Long non-coding RNA XIST regulates PDCD4 expression by interacting with miR-21-5p and inhibits osteosarcoma cell growth and metastasis. Int J Oncol (2017) 0.75
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol (2002) 17.85
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity (1995) 14.90
Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer (2005) 10.06
Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol (2002) 10.03
A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res (1981) 8.45
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med (2009) 6.80
Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell (2011) 6.21
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol (2005) 6.18
Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer (2009) 6.00
Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer (2004) 4.43
Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol (2003) 3.93
Metastasis: recent discoveries and novel treatment strategies. Lancet (2007) 3.93
Second primary neoplasms in patients with retinoblastoma. Br J Cancer (1986) 3.57
Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. J Clin Oncol (2008) 3.34
Biology and therapeutic advances for pediatric osteosarcoma. Oncologist (2004) 3.34
The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med (1986) 3.27
Bone cancers. Cancer (1995) 3.17
Initial symptoms and clinical features in osteosarcoma and Ewing sarcoma. J Bone Joint Surg Am (2000) 3.06
Limb salvage compared with amputation for osteosarcoma of the distal end of the femur. A long-term oncological, functional, and quality-of-life study. J Bone Joint Surg Am (1994) 2.93
Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev (2006) 2.85
Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev (2008) 2.74
Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1. J Clin Oncol (2012) 2.67
Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis (2007) 2.53
Platelets and cancer. Lancet Oncol (2002) 2.51
Prognostic factors in osteosarcoma: a critical review. J Clin Oncol (1994) 2.51
Limb-salvage treatment versus amputation for osteosarcoma of the distal end of the femur. J Bone Joint Surg Am (1986) 2.49
Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep (2014) 2.27
Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer (2011) 2.23
Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat Genet (2013) 2.21
Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol (2005) 2.17
Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol (1996) 2.13
Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med (1977) 2.06
Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol (2000) 2.06
Congenital telangiectatic erythema resembling lupus erythematosus in dwarfs; probably a syndrome entity. AMA Am J Dis Child (1954) 2.06
Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol (1993) 2.01
GM-CSF in inflammation and autoimmunity. Trends Immunol (2002) 2.01
Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer (2003) 1.99
Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage. Proc Natl Acad Sci U S A (2008) 1.98
Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncol (2005) 1.94
FDG PET/CT imaging in primary osseous and soft tissue sarcomas: a retrospective review of 212 cases. Eur J Nucl Med Mol Imaging (2009) 1.93
Radiation-induced sarcoma of bone. Cancer (1971) 1.92
Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol (2010) 1.92
Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev (2002) 1.84
The many faces of osteosarcoma. Radiographics (1997) 1.84
Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome. J Natl Cancer Inst (2003) 1.83
Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer (2003) 1.83
IL-28 and IL-29: newcomers to the interferon family. Biochimie (2007) 1.81
Osteosarcoma: a multidisciplinary approach to diagnosis and treatment. Am Fam Physician (2002) 1.81
Tumour-targeted nanomedicines: principles and practice. Br J Cancer (2008) 1.81
Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol (2003) 1.79
A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol (1992) 1.79
Age-specific fluoride exposure in drinking water and osteosarcoma (United States). Cancer Causes Control (2006) 1.76
CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun (2013) 1.71
Chromosomal reorganization for the expression of recessive mutation of retinoblastoma susceptibility gene in the development of osteosarcoma. Cancer Res (1988) 1.70
The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability. Proc Natl Acad Sci U S A (2003) 1.69
Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature. Clin Exp Metastasis (2011) 1.68
Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome--the French pediatric experience. Cancer (2005) 1.67
Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res (1994) 1.66
Osteosarcoma over the age of forty. Eur J Cancer (2003) 1.65
Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience. Cancer (2005) 1.55
Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. Clin Cancer Res (2011) 1.53
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol (2011) 1.40
Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. Cancer Genet Cytogenet (2000) 1.38
Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci U S A (2014) 1.36
Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival. Cancer (1995) 1.35
FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann Oncol (2001) 1.35
Radiotherapy for local control of osteosarcoma. Int J Radiat Oncol Biol Phys (2005) 1.35
Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Cancer (2009) 1.34
The genetics of osteosarcoma. Sarcoma (2012) 1.33
Frequency and structure of p53 rearrangements in human osteosarcoma. Cancer Res (1990) 1.33
Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy. J Clin Oncol (1994) 1.32
Radiation dose, chemotherapy and risk of osteosarcoma after solid tumours during childhood. Int J Cancer (1998) 1.32
The surgical treatment and outcome of pathological fractures in localised osteosarcoma. J Bone Joint Surg Br (1996) 1.31
Host related risk factors for canine osteosarcoma. Vet J (1998) 1.30
18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma. J Nucl Med (2009) 1.30
The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res (2012) 1.28
Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group. J Clin Oncol (2012) 1.27
Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. J Clin Oncol (1996) 1.26
A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis. Nat Genet (2015) 1.23
Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int (2009) 1.22
Metastases detected at the time of diagnosis of primary pediatric extremity osteosarcoma at diagnosis: imaging features. Cancer (1999) 1.22
Sarcomas of bone complicating osteitis deformans (Paget's disease): fifty years' experience. Am J Surg Pathol (1981) 1.20
Prognostic factors and outcomes for osteosarcoma: an international collaboration. Eur J Cancer (2009) 1.19
Epidemiology of osteosarcoma and Ewing's sarcoma in childhood: a study of 305 cases by the Children's Cancer Group. Cancer (1998) 1.19
Targeting HMGB1-mediated autophagy as a novel therapeutic strategy for osteosarcoma. Autophagy (2012) 1.19
Alterations of the p53, Rb and MDM2 genes in osteosarcoma. J Cancer Res Clin Oncol (1996) 1.19
Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases. J Clin Oncol (1994) 1.18
Bone cancer. J Natl Compr Canc Netw (2013) 1.17
Predictive factors for local recurrence in osteosarcoma: 540 patients with extremity tumors followed for minimum 2.5 years after neoadjuvant chemotherapy. Acta Orthop Scand (1998) 1.16
Resection of recurrent pulmonary metastases in patients with osteosarcoma. Cancer (2005) 1.16
Impact of close surgical margin on local recurrence and survival in osteosarcoma. Int Orthop (2011) 1.16
ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer (2002) 1.14
The role of cytokines in the epithelial cancer microenvironment. Semin Cancer Biol (2002) 1.13
Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor. Cancer (1985) 1.13
Late relapse of osteosarcoma: implications for follow-up and screening. Pediatr Blood Cancer (2004) 1.12